Age at Diagnosis Refines Retinoblastoma Risk Stratification

New research indicates that a child’s age at diagnosis significantly impacts the risk of developing bilateral retinoblastoma, potentially altering how genetic risk is assessed and surveillance strategies are implemented. The study, published in JAMA Ophthalmology, suggests that intensified surveillance may be warranted for infants diagnosed with retinoblastoma before 9 months of age who test positive for RB1 gene variants, whereas de-escalated monitoring could be considered for those diagnosed later.

Understanding Retinoblastoma and Genetic Risk

Retinoblastoma, a rare cancer affecting the retina, impacts roughly 1 in 16,000 to 18,000 live births [1]. The condition is often linked to mutations in the RB1 gene, which regulates cell growth. Approximately 45% of children with retinoblastoma have a hereditary form of the disease, placing them at risk for additional cancers throughout their lives [2]. While survival rates are high – exceeding 95% in high-income countries – optimizing surveillance, particularly for unilateral disease, remains a challenge.

Study Findings: Age and RB1 Status

Researchers at Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine conducted a retrospective study of 1108 children diagnosed with unilateral retinoblastoma between July 2010 and October 2024 [1]. The median age at diagnosis was 22.2 months. Over a median follow-up of 43.4 months, 2.2% of patients (24 children) developed metachronous bilateral disease – meaning the cancer appeared in the second eye after the initial diagnosis.

The risk of bilateral conversion differed significantly based on genetic status. 24.8% of patients with RB1 gene variants developed bilateral disease within 24 months, compared to just 1.6% of those without RB1 variants [1]. However, a crucial finding emerged when analyzing age at diagnosis within the RB1-positive group: those diagnosed before 9 months of age faced a substantially higher risk of fellow-eye involvement, while those diagnosed after 9 months showed no conversions.

Implications for Surveillance

These findings suggest that age at diagnosis should be considered alongside RB1 genetic status when determining surveillance strategies. The researchers propose a tiered approach:

• Intensified Surveillance: RB1 variant-positive infants diagnosed before 9 months should undergo close examination during the first 24 months.
• De-escalated Surveillance: If no conversion occurs within 24 months, surveillance can be de-escalated.
• Lower-Intensity Schedule: RB1 variant-negative patients and RB1 variant-positive children diagnosed after 9 months can be monitored with a less intensive schedule, while remaining vigilant for rare late conversions.

Hereditary Retinoblastoma: Beyond the Eye

It’s important to note that hereditary retinoblastoma isn’t limited to eye cancer. Individuals with the condition have an increased risk of other cancers, including brain tumors, sarcomas, and melanoma [3]. Early diagnosis and genetic counseling are crucial for managing these risks.

Looking Ahead

This research represents a step towards more personalized and efficient surveillance protocols for retinoblastoma. By refining risk stratification based on both genetic factors and age at diagnosis, clinicians can potentially reduce unnecessary testing and anxiety for low-risk children while ensuring timely intervention for those at higher risk. Further research is needed to validate these findings in larger, more diverse populations.